Nicotine Dependence Clinical Trial
Official title:
Glucocorticoid Antagonist Treatment for Tobacco Use Disorder
The purpose of this protocol is to examine whether mifepristone, a medication with glucocorticoid receptor antagonist activity, may be a potential treatment for Tobacco Use Disorder (TUD). Mifepristone has already shown promise as a potential treatment for PTSD (1) and alcohol use disorder (AUD) (2), but no previous studies have examined the therapeutic potential of mifepristone for TUD. This will be a double-blind, placebo-controlled study on the effects of a 7-day treatment with 600 mg mifepristone, or placebo, on cognitive function, tobacco withdrawal severity, and smoking behavior.
This will be a double-blind, placebo-controlled study that tests the effects of a 7-day
treatment with 600 mg mifepristone, or placebo, on cognitive function, tobacco withdrawal
severity and smoking behavior. Once the intake and physical examination is completed and
eligibility is determined, subjects will participate in a baseline session to become familiar
with the study procedures and to assess baseline measures of withdrawal, smoking urges, pain
sensitivity, and cognitive performance. Subjects will be asked to refrain from consuming
alcoholic beverages and drugs during their study participation. This will be verified by
urine drug screening and breathalyzer before the session and during outpatient visits. If
results indicate non-compliance with these study procedures, subjects will be discharged from
the study.
Participants will be assessed for compliance with medication treatment, withdrawal severity,
recent smoking behavior, and cognitive function during treatment visits on Days 1 and 4. On
Day 7, following overnight abstinence from smoking, participants will attend a test session
that models relapse to smoking. During this session, subjects will have the option to smoke,
or to delay smoking in exchange for monetary compensation (45). To examine if mifepristone's
proposed therapeutic effects last beyond the treatment duration (as observed in previous
studies), there will be 1-week and 1-month follow-up assessments on smoking behavior, urges
to smoke, endocrine biomarkers, and cognitive function.
Participants in each group will complete the laboratory-based, delayed smoking procedure in a
designated, negative pressure room in Bldg. 36 of the West Haven VA just after assessing pain
sensitivity with the cPT. This sequence allows the cPT to assess pain sensitivity, a
potential biomarker of relapse behavior, and to also be used as a mild stressor prior to
participation in the smoking relapse model. Participants will be instructed to abstain from
smoking after 10 pm the night before Test Sessions. Abstinence will be confirmed the morning
of the session by measuring a breath CO level of < 8 ppm.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A |